Industry Lawyers Tell US FDA Early Public Device Warnings Possibly Harmful And Confusing
This article was originally published in Clinica
Executive Summary
The US FDA’s "emerging signals" draft guidance, released Dec. 31, is already drawing criticism from device industry lawyers and advocates who complain it will unfairly cast a negative light on some medtech products, lower beneficial use of devices and provide fodder for product liability suits.